Which of the following is an inhibitor of dihydrofolate reductase?
**Core Concept:** Dihydrofolate reductase (DHFR) is an enzyme involved in the synthesis of purines and pyrimidines, which are essential for DNA and RNA synthesis. Inhibition of DHFR can lead to a deficiency in these essential building blocks, affecting cell division and causing cellular dysfunction.
**Why the Correct Answer is Right:** Trimethoprim (Option C) is a widely used antibiotic and antiprotozoal drug that acts as a competitive inhibitor of DHFR. It competitively binds to the enzyme's active site, blocking the substrate (dihydrofolate) from binding and inhibiting DHFR.
**Why Each Wrong Option is Incorrect:**
A. Pyrimethamine (Dapsone) is another antibiotic, primarily targeting Plasmodium species causing malaria and toxoplasmosis. While it is a DHFR inhibitor, it is less potent than trimethoprim and is not a competitive inhibitor.
B. Leucovorin (folinic acid) is a form of folic acid (vitamin B9), which is a co-substrate for DHFR. As a competitive inhibitor, leucovorin competes with dihydrofolate for binding to the enzyme, counteracting trimethoprim's inhibition.
C. Methotrexate (Option C) is a pyrimidine analogue that competitively inhibits DHFR. Its inhibitory effect on DHFR is a key mechanism in its action as a chemotherapeutic agent, especially in treating cancer and autoimmune diseases.
D. Hydroxyurea is a cytotoxic chemotherapy agent used in the treatment of certain cancers and sickle cell anemia. While it can inhibit DHFR to a certain extent, its primary action is through the induction of DNA synthesis inhibition and sparing of ribonucleotide reductase, which prevents DNA replication and repair.
**Clinical Pearl:** Methotrexate is used in oncology and rheumatology to treat cancer and autoimmune diseases, respectively. Its mechanism of action is related to the inhibition of DHFR, which leads to a reduction in purine and pyrimidine synthesis, ultimately affecting DNA replication and repair. This helps control cell proliferation and prevents tumor growth. In rheumatology, methotrexate targets the immune system, reducing inflammation and pain in rheumatoid arthritis and other autoimmune disorders.